P2RY12 and COVID-19: The lack of demonstrable benefit of antiplatelet therapies in patients hospitalized for COVID-19 in previous trials could be partially explained by the testing of platelet inhibitors of multiple pathways (aspirin and P2Y12 inhibitors).